. [82] to evaluate the efficacy, safety and tolerability of Cannabidiol as an adjunct therapy in addition to anti-epileptic drugs to the patients struggling from tuberous sclerosis advanced whose commonest neurological symptom is epilepsy. In this particular clinical demo analyze, immediately af